Alzheimer's disease (AD) progression varies based on the presence of tau and amyloid-beta (Aβ) proteins in the brain. Patients with high levels of both tau and Aβ experience rapid memory decline, while those with high Aβ but low tau show a slower progression. The research emphasizes that tau levels are crucial for diagnosing and managing AD effectively. This insight could lead to more personalized treatment strategies as biomarker technology advances.

Blocking the kynurenine pathway, a regulator of brain metabolism, can restore cognitive function in lab mice with Alzheimer’s disease. The pathway is overactivated in Alzheimer’s, disrupting glucose metabolism and starving neurons of energy. By inhibiting this pathway, researchers improved memory and brain plasticity in mice, offering hope for new treatments in humans. IDO1 inhibitors, currently in cancer trials, could be repurposed for Alzheimer’s treatment.

Researchers established new criteria for Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), a memory-loss condition often mistaken for Alzheimer's disease. Unlike Alzheimer’s, LANS progresses more slowly and has a better prognosis. The criteria help doctors diagnose LANS in living patients using brain scans and biomarkers. This advancement aids in better management and tailored treatments for memory loss.